Astrazeneca buys Omthera pharmaceuticals for $323 million

May 28, 2013 | By Márcio Barra

Astrazeneca announced today that it is to buy Omthera Pharmaceuticals, in an effort to strengthen its cardiovascular drug portfolio.

Following last month’s acquisition of AlphaCore Pharma, a small early-stage U.S. biotechnology company, the acquisition of Omthera Pharmaceuticals brings the drug Epanova to Astrazeneca’s surely needing portfolio. This drug is an ultra-pure mixture of the free fatty acid forms of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), two Omega 3 fatty acids from fish oil. Epanova already concluded its final-stage Phase III clinical trials, where it showed its ability to lower non-HDL cholesterol from baseline after 6 months of treatment, and is set to be submitted for U.S. regulatory approval by the middle the year.

After losing the patent for their blockbuster antipsychotic drug Seroquel last year, Astrazeneca announced back in March a massive re-structuring plan for the company, with 5050 layoffs planned, more focus on the blood thinner Brilinta, and a $240 million bet on a novel but untested technology from a small biotechnology company, Moderna Therapeutics. Acquiring Omthera Pharmaceuticals provides Astrazeneca with a late-stage asset near regulatory submission, the first since CEO Pascal Soriot presented the re-structuring plan. If Epanova is approved, it will compete with GlaxoSmithKline’s drug Lovaza, and it even has the potential to be combined with AstraZeneca’s top selling, cholesterol drug Crestor.

Brilinta, Astrazeneca’s new antiplatelet agent

AstraZeneca will buy Omthera for $12.70 per share, or approximately $323 million.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: